Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection - PubMed (original) (raw)

. 2010 Jun 15;201(12):1788-95.

doi: 10.1086/652749.

David R Jacobs Jr, Jason V Baker, Alexandra Calmy, Daniel Duprez, Alberto La Rosa, Lewis H Kuller, Sarah L Pett, Matti Ristola, Michael J Ross, Michael G Shlipak, Russell Tracy, James D Neaton

Affiliations

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection

Jacqueline Neuhaus et al. J Infect Dis. 2010.

Abstract

Background: Human immunodeficiency virus (HIV) replication and immune activation may increase inflammation and coagulation biomarkers. Limited data exist comparing such biomarkers in persons with and without HIV infection.

Methods: For persons 45-76 years of age, levels of high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals in the Strategies for Management of Anti-Retroviral Therapy (SMART) study and 5386 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) study. For persons 33-44 years of age, hsCRP and IL-6 levels were compared in 287 participants in the SMART study and 3231 participants in the Coronary Artery Development in Young Adults (CARDIA) study.

Results: hsCRP and IL-6 levels were 55% (P < . 001) and 62 (P < . 001) higher among HIV-infected participants than among CARDIA study participants. Compared with levels noted in MESA study participants, hsCRP, IL-6, D-dimer, and cystatin C levels were 50%, 152%, 94%, and 27% higher, respectively (P < . 001, for each), among HIV-infected participants. HIV-infected participants receiving antiretroviral therapy who had HIV RNA levels 400 copies/mL had levels higher (by 21% to 60%) (P < . 001) than those in the general population, for all biomarkers.

Conclusions: hsCRP, IL-6, D-dimer, and cystatin C levels are elevated in persons with HIV infection and remain so even after HIV RNA levels are suppressed with antiretroviral therapy. Additional research is needed on the pathophysiology of HIV-induced activation of inflammatory and coagulation pathways, to guide potential interventions.

PubMed Disclaimer

Conflict of interest statement

Russell Tracy reports being a paid Consultant to Abbott and Merck. No other authors have a commercial or other association that might pose a conflict of interest.

Figures

Figure 1

Figure 1

Figure 1a: Percentage Difference (HIV-infected versus General Population for hsCRP and IL-6): Participants Aged 33–44 Years. Figure 1b: Percentage Difference (HIV-infected versus General Population for hsCRP, IL-6, D-dimer and Cystatin C): Participants Aged 45–76 Years.

Figure 1

Figure 1

Figure 1a: Percentage Difference (HIV-infected versus General Population for hsCRP and IL-6): Participants Aged 33–44 Years. Figure 1b: Percentage Difference (HIV-infected versus General Population for hsCRP, IL-6, D-dimer and Cystatin C): Participants Aged 45–76 Years.

Comment in

Similar articles

Cited by

References

    1. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409–2418. - PMC - PubMed
    1. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count – guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–22296. - PubMed
    1. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. - PMC - PubMed
    1. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871–881. - PubMed
    1. Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, et al. Cardiovascular Risk Factors in Young Adults. The CARDIA Baseline Monograph. Cont Clin Trials. 1991;12(Supplement):1S–78S. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources